Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment : Is There Still Hope?

Show simple item record

dc.contributor.author Hyytiäinen, Aini
dc.contributor.author Wahbi, Wafa
dc.contributor.author Väyrynen, Otto
dc.contributor.author Saarilahti, Kauko
dc.contributor.author Karihtala, Peeter
dc.contributor.author Salo, Tuula
dc.contributor.author Al-Samadi, Ahmed
dc.date.accessioned 2021-09-01T07:56:01Z
dc.date.available 2021-09-01T07:56:01Z
dc.date.issued 2021-06-14
dc.identifier.citation Hyytiäinen , A , Wahbi , W , Väyrynen , O , Saarilahti , K , Karihtala , P , Salo , T & Al-Samadi , A 2021 , ' Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment : Is There Still Hope? ' , Frontiers in oncology , vol. 11 , 683570 . https://doi.org/10.3389/fonc.2021.683570
dc.identifier.other PURE: 168062559
dc.identifier.other PURE UUID: 72b363f2-9399-4989-8afc-c4e2bafbae4a
dc.identifier.other WOS: 000667195000001
dc.identifier.other ORCID: /0000-0001-6039-0088/work/99330954
dc.identifier.other ORCID: /0000-0003-3490-3702/work/101303373
dc.identifier.uri http://hdl.handle.net/10138/333884
dc.description.abstract Background Head and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression. Therefore, several agents targeting the pathways that mediate angiogenesis have been developed. We conducted a systematic review to summarise the current clinical trial data examining angiogenesis inhibitors in HNSCC. Methods We carried out a literature search on three angiogenesis inhibitor categories-bevacizumab, tyrosine kinase inhibitors and endostatin-from Ovid MEDLINE, Cochrane Library, Scopus and ClinicalTrials.gov database. Results Here, we analysed 38 clinical trials, total of 1670 patients, investigating 12 angiogenesis inhibitors. All trials were in phase I or II, except one study in phase III on bevacizumab. Angiogenesis inhibitors were used as mono- and combination therapies together with radio-, chemo-, targeted- or immunotherapy. Among 12 angiogenesis inhibitors, bevacizumab was the most studied drug, included in 13 trials. Although bevacizumab appeared effective in various combinations, it associated with high toxicity levels. Endostatin and lenvatinib were well-tolerated and their anticancer effects appeared promising. Conclusions Most studies did not show benefit of angiogenesis inhibitors in HNSCC treatment. Additionally, angiogenesis inhibitors were associated with considerable toxicity. However, some results appear encouraging, suggesting that further investigations of angiogenesis inhibitors, particularly in combination therapies, for HNSCC patients are warranted. Systematic Review Registration PROSPERO (https://www.crd.york.ac.uk/prospero/), identifier CRD42020157144. en
dc.format.extent 23
dc.language.iso eng
dc.relation.ispartof Frontiers in oncology
dc.rights cc_by
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject anti-angiogenesis
dc.subject head and neck cancer
dc.subject therapy
dc.subject endostatin
dc.subject bevacizumab
dc.subject PHASE-II-TRIAL
dc.subject ADVANCED NASOPHARYNGEAL CARCINOMA
dc.subject RECOMBINANT HUMAN ENDOSTATIN
dc.subject AND/OR METASTATIC HEAD
dc.subject LOCALLY ADVANCED HEAD
dc.subject RADIATION-THERAPY
dc.subject CONCURRENT CHEMORADIATION
dc.subject HEPATOCELLULAR-CARCINOMA
dc.subject TARGETING ANGIOGENESIS
dc.subject TUMOR ANGIOGENESIS
dc.subject 3122 Cancers
dc.title Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment : Is There Still Hope? en
dc.type Review Article
dc.contributor.organization Research Programs Unit
dc.contributor.organization Department of Oral and Maxillofacial Diseases
dc.contributor.organization Clinicum
dc.contributor.organization University of Helsinki
dc.contributor.organization TRIMM - Translational Immunology Research Program
dc.contributor.organization Faculty of Medicine
dc.contributor.organization HUS Comprehensive Cancer Center
dc.contributor.organization Department of Oncology
dc.contributor.organization HUSLAB
dc.contributor.organization Department of Pathology
dc.contributor.organization HUS Head and Neck Center
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.3389/fonc.2021.683570
dc.relation.issn 2234-943X
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
fonc_11_683570.pdf 991.8Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record